NO20061598L - Sulfonamidderivater til behandling av diabetes - Google Patents

Sulfonamidderivater til behandling av diabetes

Info

Publication number
NO20061598L
NO20061598L NO20061598A NO20061598A NO20061598L NO 20061598 L NO20061598 L NO 20061598L NO 20061598 A NO20061598 A NO 20061598A NO 20061598 A NO20061598 A NO 20061598A NO 20061598 L NO20061598 L NO 20061598L
Authority
NO
Norway
Prior art keywords
group
sulfonamide
treatment
hydrogen
nitrogen atom
Prior art date
Application number
NO20061598A
Other languages
English (en)
Norwegian (no)
Inventor
Jean-Pierre Gotteland
Pierre-Alain Vitte
Thomas Rueckle
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20061598L publication Critical patent/NO20061598L/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/18Sulfonamides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NO20061598A 2003-09-12 2006-04-07 Sulfonamidderivater til behandling av diabetes NO20061598L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03102742 2003-09-12
PCT/EP2004/052143 WO2005025558A1 (fr) 2003-09-12 2004-09-13 Derives de sulfonamide pour le traitement du diabete

Publications (1)

Publication Number Publication Date
NO20061598L true NO20061598L (no) 2006-06-09

Family

ID=34306923

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20061598A NO20061598L (no) 2003-09-12 2006-04-07 Sulfonamidderivater til behandling av diabetes

Country Status (10)

Country Link
US (1) US7705052B2 (fr)
EP (1) EP1663193B1 (fr)
JP (1) JP4870562B2 (fr)
AT (1) ATE551997T1 (fr)
AU (1) AU2004271741A1 (fr)
CA (1) CA2534312A1 (fr)
ES (1) ES2385219T3 (fr)
IL (1) IL174251A0 (fr)
NO (1) NO20061598L (fr)
WO (1) WO2005025558A1 (fr)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4414219B2 (ja) * 2001-07-23 2010-02-10 メルク セローノ ソシエテ アノニム C−jun−n−末端キナーゼ(jnk)インヒビターとしてのアリールスルホンアミド誘導体
ATE551997T1 (de) 2003-09-12 2012-04-15 Merck Serono Sa Sulfonamid-derivate zur behandlung von diabetes
AU2011265521B8 (en) * 2005-07-15 2014-05-22 Merck Serono Sa JNK inhibitors for the treatment of endometreosis
BRPI0520579B8 (pt) * 2005-08-12 2021-05-25 Suven Life Sciences Ltd composto, processo para a preparação de um composto e composição farmacêutica
JP5301465B2 (ja) 2007-01-25 2013-09-25 バーバ・ファーマシューティカルズ・リミテッド インスリン抵抗性改善薬および治療方法
US8507746B2 (en) * 2008-12-16 2013-08-13 Kimberly-Clark Worldwide, Inc. Leakage-signaling absorbent article
US8225729B2 (en) * 2008-12-16 2012-07-24 Kimberly-Clark Worldwide, Inc. Three-dimensional wiping substrate and method therefor
US8882735B2 (en) * 2008-12-16 2014-11-11 Kimberly-Clark Worldwide, Inc. Article with fluid-activated barriers
US7858055B2 (en) * 2008-12-18 2010-12-28 Kimberly-Clark Worldwide, Inc. Moisture sensitive auxetic material
US8993808B2 (en) 2009-01-21 2015-03-31 Oryzon Genomics, S.A. Phenylcyclopropylamine derivatives and their medical use
US8859555B2 (en) 2009-09-25 2014-10-14 Oryzon Genomics S.A. Lysine Specific Demethylase-1 inhibitors and their use
EP2486002B1 (fr) 2009-10-09 2019-03-27 Oryzon Genomics, S.A. Acétamides d'hétéroaryl- et aryl-cyclopropylamine substitués et leur utilisation
WO2011106106A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs de lysine déméthylase pour lutter contre les maladies et troubles associés à l'hepadnaviridae
WO2011106574A2 (fr) 2010-02-24 2011-09-01 Oryzon Genomics, S.A. Inhibiteurs destinés à une utilisation antivirale
CA2796726C (fr) 2010-04-19 2021-02-16 Oryzon Genomics S.A. Inhibiteurs de la demethylase-1 specifiques de la lysine, et leur utilisation
WO2011153359A1 (fr) * 2010-06-04 2011-12-08 Albany Molecular Research, Inc. Inhibiteurs du transporteur 1 de la glycine, procédés de fabrication associés, et utilisations associées
US9006449B2 (en) 2010-07-29 2015-04-14 Oryzon Genomics, S.A. Cyclopropylamine derivatives useful as LSD1 inhibitors
BR112013002164B1 (pt) 2010-07-29 2021-11-09 Oryzon Genomics S.A. Inibidores de desmetilase à base de arilciclopropilamina de lsd1, seus usos, e composição farmacêutica
JP2013536233A (ja) * 2010-08-23 2013-09-19 アムジエン・インコーポレーテツド グルコキナーゼ調節タンパク質と相互作用する糖尿病治療用の化合物
US9061966B2 (en) 2010-10-08 2015-06-23 Oryzon Genomics S.A. Cyclopropylamine inhibitors of oxidases
WO2012072713A2 (fr) 2010-11-30 2012-06-07 Oryzon Genomics, S.A. Inhibiteurs de la déméthylase spécifique de la lysine pour des maladies et troubles liés aux flaviviridés
US8708988B2 (en) 2010-12-03 2014-04-29 Kimberly-Clark Worldwide, Inc. Absorbent article configured for controlled deformation
EP2712315B1 (fr) 2011-02-08 2021-11-24 Oryzon Genomics, S.A. Inhibiteurs de lysine déméthylase pour des troubles myéloprolifératifs
EP2768805B1 (fr) * 2011-10-20 2020-03-25 Oryzon Genomics, S.A. Composés (hétéro)aryl cyclopropyl comme inhibiteurs de lsd1
JP6046154B2 (ja) 2011-10-20 2016-12-14 オリソン ヘノミクス エセ. アー. Lsd1阻害剤としての(ヘテロ)アリールシクロプロピルアミン化合物
JP6540505B2 (ja) * 2013-03-29 2019-07-10 国立大学法人 熊本大学 2型糖尿病治療剤
JP6602779B2 (ja) 2014-02-13 2019-11-06 インサイト・コーポレイション Lsd1阻害剤としてのシクロプロピルアミン類
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105218B1 (fr) * 2014-02-13 2019-09-25 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
EP3105219B9 (fr) 2014-02-13 2018-10-03 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
US9695180B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,2-a]pyrazines as LSD1 inhibitors
EA039196B1 (ru) * 2014-10-08 2021-12-16 Инсайт Корпорейшн Циклопропиламины в качестве ингибиторов lsd1
EP3277689B1 (fr) 2015-04-03 2019-09-04 Incyte Corporation Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
MY189367A (en) 2015-08-12 2022-02-08 Incyte Corp Salts of an lsd1 inhibitor
TWI833686B (zh) 2016-04-22 2024-03-01 美商英塞特公司 Lsd1 抑制劑之調配物
US10683292B2 (en) * 2016-07-25 2020-06-16 Nerviano Medical Sciences S.R.L. Purine and 3-deazapurine analogues as choline kinase inhibitors
US10968200B2 (en) 2018-08-31 2021-04-06 Incyte Corporation Salts of an LSD1 inhibitor and processes for preparing the same
CN119462614B (zh) * 2025-01-14 2025-05-02 吉林大学 1-mhmd、制备方法及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3174901A (en) * 1963-01-31 1965-03-23 Jan Marcel Didier Aron Samuel Process for the oral treatment of diabetes
US3454635A (en) * 1965-07-27 1969-07-08 Hoechst Ag Benzenesulfonyl-ureas and process for their manufacture
US4927831A (en) 1988-10-20 1990-05-22 American Home Products Spiro-isoquinoline-pyrrolidine tetrones and analogs thereof useful as aldose reductase inhibitors
CZ302691B6 (cs) * 1998-07-08 2011-09-07 Sanofi - Aventis Deutschland GmbH N-Arylamidová sloucenina, zpusob její prípravy, farmaceutický prostredek tuto slouceninu obsahující, tato sloucenina pro použití jako aktivátor a pro použití k terapii nebo profylaxi
EP1088821A1 (fr) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Derives des sulfamides pharmaceutiquement actifs
EP1088815A1 (fr) * 1999-09-28 2001-04-04 Applied Research Systems ARS Holding N.V. Dérivés d'acides amines sulphonyle pharmaceutiquement actifs
EP1193267A1 (fr) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Composés de sulfonamides hydrophiles pharmaceutiquement actifs
EP1193256A1 (fr) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Derivés de benzénesulphonamide pharmaceutiquemant actifs comme inhibiteurs de protéines JNK
EP1193268A1 (fr) * 2000-09-27 2002-04-03 Applied Research Systems ARS Holding N.V. Dérivés de sulfonamide pharmaceutiquement actifs comportant des groupes lipophiles ainsi que ionisables comme inhibiteurs de protéine junkinases
WO2002100396A1 (fr) 2001-06-07 2002-12-19 Wyeth Combinaison d'un inhibiteur de la ptpase et d'un agent thiazolidinedione
JP4414219B2 (ja) * 2001-07-23 2010-02-10 メルク セローノ ソシエテ アノニム C−jun−n−末端キナーゼ(jnk)インヒビターとしてのアリールスルホンアミド誘導体
ATE551997T1 (de) 2003-09-12 2012-04-15 Merck Serono Sa Sulfonamid-derivate zur behandlung von diabetes

Also Published As

Publication number Publication date
AU2004271741A1 (en) 2005-03-24
EP1663193B1 (fr) 2012-04-04
JP4870562B2 (ja) 2012-02-08
WO2005025558A1 (fr) 2005-03-24
JP2007505088A (ja) 2007-03-08
IL174251A0 (en) 2006-08-01
CA2534312A1 (fr) 2005-03-24
ATE551997T1 (de) 2012-04-15
EP1663193A1 (fr) 2006-06-07
US7705052B2 (en) 2010-04-27
ES2385219T3 (es) 2012-07-19
US20070043027A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
NO20061598L (no) Sulfonamidderivater til behandling av diabetes
AU2005314155C1 (en) Method for preparing N-phenylpyrazole-1-carboxamides
ES2572155T3 (es) Compuestos insecticidas
EP1873144A4 (fr) Compose heterocyclique fusionne
NO20083480L (no) Piperidinoylpyrrolidiner som melanokortin type 4 reseptor agonister
EA200870470A1 (ru) Ингибиторы 11-бета-гидроксистероид дегидрогеназы 1
ATE472531T1 (de) Sulfonylverbindungen als hemmer von 11-beta- hydroxysteroiddehydrogenase-1
PE20091842A1 (es) Pirrolidinonas como activadores de glucoquinasa
DK2029529T3 (da) Substitueret pyrrolidinone som inhibitor af 11-beta-hydroxysteroiddehydrogenase 1
EA200600527A1 (ru) Активирующее ppar соединение и содержащая его фармацевтическая композиция
ATE523507T1 (de) Piperidin-gpcr-agonisten
WO2008155668A3 (fr) Composés hétéroarylamide pyrimidone
MX2010008361A (es) Derivados de arilamida oxazepinopirimidona sustituidos.
NO20072382L (no) (S)-(-)-1-(4-Fluorisokinolin-5-yl)-sulfonyl-2-metyl-1,4-homopiperazinhydroklorid dihydrat
MX2009012377A (es) Compuestos de arilamida pirimidona.
MX2010008362A (es) Derivados de heteroarilamida diazepinopirimidona sustituidos.
WO2008155669A3 (fr) Dérivés de pyrimidone arylamide
ATE455772T1 (de) Alkinylarylcarbonsäureamide
NO20061614L (no) Benzimidazolacetonitriler
UA86836C2 (ru) Производные изоксазолина, способ их получения (варианты), гербицидная композиция и способ угнетения роста сорняков
CY1113042T1 (el) Αντιμετωπιση μυϊασης
DE602004024170D1 (de) Pyrrolidin-derivate als oxytocin antagonisten
TH104958A (fr)
TH109166A (th) อะโกนิสต์ของ gpcr
TH98281A (th) สารประกอบไซคลิกหลอม

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

FC2A Withdrawal, rejection or dismissal of laid open patent application